Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%

Cstone Pharmaceuticals (HKG:2616) reported a loss for the year attributable to owners of about 367.2 million yuan, down from a loss of 902.7 yuan in the previous year, according to the annual results

MT NewswiresApr 24 03:57 ET

基石藥業-B：2023年年報

Futu NewsApr 23 05:00 ET · Announcements

China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor

China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong

MT NewswiresApr 8 21:52 ET

Cornerstone Pharmaceutical-B (02616.HK): The application for marketing registration of the RET inhibitor Pujihua (platinib capsules) transferred from overseas to domestically produced drugs has been accepted by the Drug Evaluation Center of the State Drug

Gelonghui, April 9 | Cornerstone Pharmaceutical-B (02616.HK) announced that the application for the transfer of the RET inhibitor Pujihua (Platinib capsules) to domestically produced drugs has been accepted by the China National Drug Administration (NMPA) Drug Evaluation Center. Previously, Cornerstone Pharmaceuticals' application for marketing registration to transfer another precision medicine, Taijihua (avatinib tablets), to be produced domestically was accepted by the Drug Review Center in June 2023. It is currently under review, and domestic supply is expected to be achieved in 2024. Dr. Yang Jianxin, CEO and Executive Director of Cornerstone Pharmaceuticals, said, “Phuket China

Gelonghui FinanceApr 8 20:05 ET

Cornerstone Pharmaceutical-B (02616) granted a total of 11.1979 million restricted share units and 11.20.29 million share options

Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616) issued an announcement. On March 28, 2024, the board of directors of the company decided to grant a total of 11.1979 million restricted share units to 104 restricted share unit grantees in accordance with the restricted share award scheme after the initial public offering. On March 28, 2024, the board of directors of the company decided to grant a total of 11.202,900 share options to 107 share option grantees in accordance with the post-initial public offering employee share ownership plan.

Zhitong FinanceMar 28 14:36 ET

Cornerstone Pharmaceutical-B (02616.HK) announced annual results, losses were drastically reduced by 59.3% and will continue to promote innovative pipeline drugs

On March 27, GLONGHUI | Cornerstone Pharmaceutical-B (02616.HK) announced that for the year ended December 31, 2023, the company's revenue was RMB 463.8 million. The loss during the year decreased from RMB 902.7 million in the previous year to RMB 535.5 million or 59.3% to RMB 367.2 million in the year, mainly due to a sharp reduction in employee costs and the net profit from the transfer of the avonib business. The company continues to develop and deepen relationships with major global strategic partners (including partners in China) and expand commercialization of marketed and advanced drugs,

Gelonghui FinanceMar 27 09:21 ET